{"nctId":"NCT04568434","briefTitle":"A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)","startDateStruct":{"date":"2020-11-18","type":"ACTUAL"},"conditions":["Familial Chylomicronemia Syndrome"],"count":66,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Olezarsen 50 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Olezarsen"]},{"label":"Olezarsen 80 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Olezarsen"]}],"interventions":[{"name":"Olezarsen","otherNames":["ISIS 678354","AKCEA-APOCIII-LRx"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* A diagnosis of genetically confirmed Familial Chylomicronemia Syndrome (type 1 Hyperlipoproteinemia)\n* Fasting TG ≥ 880 mg/dL (10 millimoles per liter (mmol/L) at Screening\n* History of pancreatitis. Patients without a documented history of pancreatitis are also eligible but their enrollment will be capped at 35%\n* Stable doses of statins, omega-3 fatty acids, fibrates, or other lipid-lowering medications are allowed\n\nKey Exclusion Criteria:\n\n* Acute coronary syndrome within 6 months of Screening\n* Major surgery within 3 months of Screening\n* Have any other conditions, which, in the opinion of the Investigator would make the participant unsuitable for inclusion, or could interfere with participating in or completing the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Fasting TG at Month 6","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.52","spread":null},{"groupId":"OG001","value":"-10.85","spread":null},{"groupId":"OG002","value":"-31.99","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting TG at Month 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.89","spread":null},{"groupId":"OG001","value":"-22.92","spread":null},{"groupId":"OG002","value":"-38.50","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Apolipoprotein C-III (apoC-III) at Months 6 and 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.57","spread":null},{"groupId":"OG001","value":"-57.91","spread":null},{"groupId":"OG002","value":"-66.13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.08","spread":null},{"groupId":"OG001","value":"-59.98","spread":null},{"groupId":"OG002","value":"-64.20","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With ≥ 40% Reduction in Fasting TG at Month 6","description":"Percentages are rounded off to the nearest single decimal place.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":null},{"groupId":"OG001","value":"33.3","spread":null},{"groupId":"OG002","value":"40.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Apolipoprotein B-48 (apoB-48) at Months 6 and 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.50","spread":null},{"groupId":"OG001","value":"-8.78","spread":null},{"groupId":"OG002","value":"-59.46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.52","spread":null},{"groupId":"OG001","value":"-36.41","spread":null},{"groupId":"OG002","value":"-79.15","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Months 6 and 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.33","spread":null},{"groupId":"OG001","value":"-12.35","spread":null},{"groupId":"OG002","value":"-18.86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.01","spread":null},{"groupId":"OG001","value":"-17.84","spread":null},{"groupId":"OG002","value":"-27.69","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjudicated Acute Pancreatitis Mean Event Rate Per 100 Participant-Years During the Treatment Period (Week 1 Through Week 53) in Participants With Prior History of Pancreatitis","description":"All AEs and SAEs that consistently occurred during the study with an event of acute pancreatitis were adjudicated by a blinded, independent committee according to the Atlanta classification of acute pancreatitis as outlined in the Acute Pancreatitis Adjudication Committee (PAC) Charter. These events were categorized as 1) documented pancreatitis, 2) probable pancreatitis, 3) possible pancreatitis, 4) unable to adjudicate and 5) no diagnosis of acute pancreatitis. The adjudicated event rate represents the average number of events per 100 participant-years during the treatment period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.22","spread":null},{"groupId":"OG001","value":"6.73","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjudicated Acute Pancreatitis Mean Event Rate Per 100 Participant-Years During the Treatment Period (Week 1 Through Week 53)","description":"All AEs and SAEs that consistently occurred during the study with an event of acute pancreatitis were adjudicated by a blinded, independent committee according to the Atlanta classification of acute pancreatitis as outlined in the PAC Charter. These events were categorized as 1) documented pancreatitis, 2) probable pancreatitis, 3) possible pancreatitis, 4) unable to adjudicate and 5) no diagnosis of acute pancreatitis. The adjudicated event rate represents the average number of events per 100 participant-years during the treatment period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.31","spread":null},{"groupId":"OG001","value":"4.37","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjudicated Acute Pancreatitis Mean Event Per 100 Participant-Years Rate During Week 13 Through Week 53 in Participants With Prior History of Pancreatitis","description":"All AEs and SAEs that consistently occurred during the study with an event of acute pancreatitis were adjudicated by a blinded, independent committee according to the Atlanta classification of acute pancreatitis as outlined in the PAC Charter. These events were categorized as 1) documented pancreatitis, 2) probable pancreatitis, 3) possible pancreatitis, 4) unable to adjudicate and 5) no diagnosis of acute pancreatitis. The adjudicated event rate represents the average number of events per 100 participant-years during the specified duration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.89","spread":null},{"groupId":"OG001","value":"8.17","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjudicated Acute Pancreatitis Mean Event Rate Per 100 Participant-Years During Week 13 to Week 53","description":"All AEs and SAEs that consistently occurred during the study with an event of acute pancreatitis were adjudicated by a blinded, independent committee according to the Atlanta classification of acute pancreatitis as outlined in the PAC Charter. These events were categorized as 1) documented pancreatitis, 2) probable pancreatitis, 3) possible pancreatitis, 4) unable to adjudicate and 5) no diagnosis of acute pancreatitis. The adjudicated event rate represents the average number of events per 100 participant-years during the specified duration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.43","spread":null},{"groupId":"OG001","value":"5.42","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With ≥ 70% Reduction in Fasting TG at Month 6","description":"Percentages are rounded off to the nearest single decimal place.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4.8","spread":null},{"groupId":"OG002","value":"9.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Fasting TG ≤ 880 mg/dL at Month 6","description":"Percentages are rounded off to the nearest single decimal place.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"10.0","spread":null},{"groupId":"OG002","value":"14.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjudicated Acute Pancreatitis Mean Event Rate Per 100 Participant-Years During Treatment Period in Participants With ≥ 2 Events in 5 Years Prior to Enrollment","description":"All AEs and SAEs that consistently occurred during the study with an event of acute pancreatitis were adjudicated by a blinded, independent committee according to the Atlanta classification of acute pancreatitis as outlined in the PAC Charter. These events were categorized as 1) documented pancreatitis, 2) probable pancreatitis, 3) possible pancreatitis, 4) unable to adjudicate and 5) no diagnosis of acute pancreatitis. The adjudicated event rate represents the average number of events per 100 participant-years during the treatment period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"118.59","spread":null},{"groupId":"OG001","value":"16.59","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjudicated Acute Pancreatitis Mean Event Rate Per 100 Participant-Years From Week 13 to Week 53 in Participants With ≥ 2 Events in 5 Years Prior to Enrollment","description":"All AEs and SAEs that consistently occurred during the study with an event of acute pancreatitis were adjudicated by a blinded, independent committee according to the Atlanta classification of acute pancreatitis as outlined in the PAC Charter. These events were categorized as 1) documented pancreatitis, 2) probable pancreatitis, 3) possible pancreatitis, 4) unable to adjudicate and 5) no diagnosis of acute pancreatitis. The adjudicated event rate represents the average number of events per 100 participant-years during the specified duration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"106.91","spread":null},{"groupId":"OG001","value":"21.36","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Fasting TG ≤ 500 mg/dL at Month 6","description":"Percentages are rounded off to the nearest single decimal place.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"13.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":23},"commonTop":["COVID-19","Abdominal pain","Diarrhoea","Headache","Fatigue"]}}}